Strengthening Causal Inference from Randomised Controlled Trials of Complex Interventions
Overview
Authors
Affiliations
Researchers conducting randomised controlled trials (RCTs) of complex interventions face design and analytical challenges that are not fully addressed in existing guidelines. Further guidance is needed to help ensure that these trials of complex interventions are conducted to the highest scientific standards while maximising the evidence that can be extracted from each trial. The key challenge is how to manage the multiplicity of outcomes required for the trial while minimising false positive and false negative findings. To address this challenge, we formulate three principles to conduct RCTs: (1) outcomes chosen should be driven by the intent and programme theory of the intervention and should thus be linked to testable hypotheses; (2) outcomes should be adequately powered and (3) researchers must be explicit and fully transparent about all outcomes and hypotheses before the trial is started and when the results are reported. Multiplicity in trials of complex interventions should be managed through careful planning and interpretation rather than through post hoc analytical adjustment. For trials of complex interventions, the distinction between primary and secondary outcomes as defined in current guidelines does not adequately protect against false positive and negative findings. Primary outcomes should be defined as outcomes that are relevant based on the intervention intent and programme theory, declared (ie, registered), and adequately powered. The possibility of confirmatory causal inference is limited to these outcomes. All other outcomes (either undeclared and/or inadequately powered) are secondary and inference relative to these outcomes will be exploratory.
Omosa E, Cattaneo F, Kibbee M, Dominguez-Salas P, Bishop N, Brouwer I Campbell Syst Rev. 2025; 21(1):e70030.
PMID: 40065775 PMC: 11891923. DOI: 10.1002/cl2.70030.
Piolanti A, Mueller J, Waller F, Heinrichs N, Simon J, Shenderovich Y BMJ Open. 2025; 15(2):e094085.
PMID: 39920046 PMC: 11808879. DOI: 10.1136/bmjopen-2024-094085.
Catherine N, MacMillan H, Jack S, Zheng Y, Xie H, Boyle M BMJ Open. 2025; 15(1):e083147.
PMID: 39762105 PMC: 11749688. DOI: 10.1136/bmjopen-2023-083147.
Assessing the Impact of D-Dimer on Stroke Diagnosis Within 24 h.
Tzeng I, Yiang G, Wu M, Chen M J Clin Lab Anal. 2024; 38(24):e25133.
PMID: 39639587 PMC: 11659750. DOI: 10.1002/jcla.25133.
Asige E, Saloojee G, Andrews C, Namaganda L, Kakooza-Mwesige A, Damiano D Dev Med Child Neurol. 2024; 67(1):87-98.
PMID: 38922854 PMC: 11625466. DOI: 10.1111/dmcn.16007.